SOCS1
SOCS1 (Suppressor of cytokine signalling 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Rectal cancer.
Overview
Essential negative regulator of type I and type II interferon (IFN) signalling, as well as that of other cytokines, including IL2, IL4, IL6 and leukaemia inhibitory factor (LIF). Down-regulates cytokine signalling by inhibiting the JAK/STAT signalling pathway. Acts by binding to JAK proteins and to IFNGR1 and inhibiting their kinase activity.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.49 (direct and indirect evidence; datatypes literature 0.99, animal model 0.51, genetic association 0.04, somatic mutation 0.74). IntOGen calls it a driver in 5 cohorts (3 activating, 2 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma, Rectal Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SOCS1 (Suppressor of cytokine signalling 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Rectal cancer.
- 1 · What it is
SOCS1 (Suppressor of cytokine signalling 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Rectal cancer.
- 2 · What goes wrong in cancer
Essential negative regulator of type I and type II interferon (IFN) signalling, as well as that of other cytokines, including IL2, IL4, IL6 and leukaemia inhibitory factor (LIF).
- 3 · How drugs use it
No product in this corpus aims at SOCS1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:19383 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15524 (protein name, function text, keywords and locations (REST API)); CIViC gene SOCS1 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000185338 (association with cancer (MONDO_0004992) 0.49; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.63, non-Hodgkin lymphoma 0.68 (GraphQL API, CC0)); IntOGen SOCS1 (driver in 5 cohorts (Act 3, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Essential negative regulator of type I and type II interferon (IFN) signalling, as well as that of other cytokines, including IL2, IL4, IL6 and leukaemia inhibitory factor (LIF). Down-regulates cytokine signalling by inhibiting the JAK/STAT signalling pathway. Acts by binding to JAK proteins and to IFNGR1 and inhibiting their kinase activity. In vitro, suppresses Tec protein-tyrosine activity. Regulates IFN-gamma (IFNG)-mediated sensory neuron survival. Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Location: Nucleus; Cytoplasmic vesicle (UniProt). Locus 16p13.13 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.68 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)
- Diffuse large B-cell lymphoma: Open Targets association 0.63 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease
- Rectal cancer: IntOGen driver in 1 cohort (READ)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SOCS1" OR ABSTRACT:"SOCS1" OR TITLE:"suppressor of cytokine signaling 1" OR ABSTRACT:"suppressor of cytokine signaling 1" OR TITLE:"Suppressor of cytokine signaling 1" OR ABSTRACT:"Suppressor of cytokine signaling 1" OR TITLE:"SOCS-1" OR ABSTRACT:"SOCS-1" OR TITLE:"SSI-1" OR ABSTRACT:"SSI-1" OR TITLE:"TIP3" OR ABSTRACT:"TIP3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SOCS1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNFATC2
Shares Rectal cancer, IntOGen, Open Targets Platform.
- TargetTCF7L2
Shares Rectal cancer, IntOGen, Open Targets Platform.
- TargetAMER1
Shares Rectal cancer, IntOGen, Open Targets Platform.
- TargetMSH2
Shares Rectal cancer, CIViC, Open Targets Platform.